Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer
- 1 May 2003
- Vol. 61 (5) , 993-998
- https://doi.org/10.1016/s0090-4295(02)02583-9
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- PYRIDINOLINE CROSS-LINKED CARBOXYTERMINAL TELOPEPTIDE OF TYPE I COLLAGEN AS A USEFUL MARKER FOR MONITORING METASTATIC BONE ACTIVITY IN MEN WITH PROSTATE CANCERJournal of Urology, 2001
- Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancerThe Prostate, 1999
- Prognostic Significance of Extent of Disease in Bone in Patients With Androgen-Independent Prostate CancerJournal of Clinical Oncology, 1999
- Inability of bone turnover marker as a strong prognostic indicator in prostate cancer patients with bone metastasis: Comparison with the extent of disease (EOD) gradeThe Prostate, 1999
- The Value of Serum Carboxyterminal Propeptide of Type 1 Procollagen in Predicting Bone Metastases in Prostate CancerJournal of Urology, 1997
- Lack of Correlation Between Prostate-Specific Antigen and the Presence of Measurable Soft Tissue Metastases in Hormone-Refractory Prostate CancerCancer Investigation, 1996
- Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancerBritish Journal of Cancer, 1995
- Some Limitations of the Radioisotope Bone Scan in Patients With Metastatic Prostatic CancerCancer, 1990
- Generalised Increase in Bone Resorption in Carcinoma of the ProstateBritish Journal of Urology, 1985
- A comparison of the sensitivity and accuracy of the 99Tcm-phosphate bone scan and skeletal radiograph in the diagnosis of bone metastasesClinical Radiology, 1977